Referral: Tecovirimat SIGA, tecovirimat Article 20 procedures European Commission final decision, 26/03/2026, 29/05/2026, 15/06/2026

Human medicines European public assessment report (EPAR): Tecovirimat SIGA, tecovirimat monohydrate, Date of authorisation: 06/01/2022, Revision: 6, Status: Authorised

Webinar on the use of platform approaches in the non-clinical and clinical domains, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 2 March 2026, 09:25 (CET) to 2 March 2026, 12:30 (CET)

Committee for Medicinal Products for Veterinary Use (CVMP): 10-12 March 2026, European Medicines Agency, Amsterdam, the Netherlands, from 10 March 2026 to 12 March 2026

EMA Management Board: highlights of June 2026 meeting

Human medicines European public assessment report (EPAR): Sitagliptin / Metformin hydrochloride Mylan, sitagliptin hydrochloride monohydrate,metformin hydrochloride, Date of authorisation: 16/02/2022, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Tadalafil Mylan, tadalafil, Date of authorisation: 21/11/2014, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Tuyory, tocilizumab, Date of authorisation: 27/04/2026, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Zutectra, human hepatitis B immunoglobulin, Date of authorisation: 30/11/2009, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Emtricitabine/Tenofovir disoproxil Mylan, emtricitabine,tenofovir disoproxil, Date of authorisation: 16/12/2016, Revision: 18, Status: Authorised